ClinicalTrials.gg
Not yet recruitingNCT07948005VEGAUpdated Nov 19, 2026

A Long-Term Follow-Up Study of Subjects With Stargardt Disease (STGD1) Treated With SB-007

An observational study in Stargardt Disease, Stargardt Macular Degeneration and Stargardt Macular Dystrophy, sponsored by Splice Bio. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Splice Bio · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
55
Sex
All
01

Study summary

This study will evaluate the long-term safety of subretinal SB-007 administration in subjects with Stargardt Disease Type 1 (STGD1).

This is a multicenter study which will follow subjects over a 164-week period after completion of an antecedent SB-007 interventional trial.

02

Conditions studied

  • Stargardt Disease
  • Stargardt Macular Degeneration
  • Stargardt Macular Dystrophy

Browse trials for

Keywords

  • Gene Therapy
  • SB-007
  • SpliceBio
  • Stargardt
  • Stargardts Disease
  • STGD1
03

In context

Stargardt Disease

68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.

This study's planned enrollment of 55 is close to the median of 50 across 25 observational studies indexed under Stargardt Disease.

Browse Stargardt Disease studies →

Lead sponsor

Splice Bio is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All subjects who were previously enrolled in and were treated with SB-007 in an antecedent SB-007 interventional trial and who meet the eligibility criteria for this study will be invited to participate.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for study participation, subjects must meet the following criteria:

  1. Provide written consent. Subjects under legal age will also provide informed assent according to guidelines set forth by the same.
  2. Previously enrolled in and treated with SB-007 in an antecedent SB-007 interventional trial.

Exclusion criteria

Exclusion Criteria:

Subjects must be excluded from participating in the study if they:

1. Are unwilling to follow the requirements of the LTFU study, including study visits and assessments.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
55 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subjects with STGD1 previously treated with SB-007

    All subjects previously treated with SB-007

    Drug: No new intervention

Interventions

  • DrugNo new intervention

    This is an observational long-term follow-up (LTFU) study of subjects with STGD1 who were previously treated with SB-007 in an antecedent SB-007 interventional trial. There is no new intervention involved in this LTFU study.

06

What researchers measure

Primary outcomes

  1. Long-term safety of SB-007

    Long-term safety of SB-007, as assessed by all ocular and non-ocular AEs

    Time frame: 164 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2035, 108 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 31, 2035
CompletionEst.
Dec 31, 2035
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07948005
Lead sponsor
Splice Bio
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2035 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Nov 19, 2026

Study contacts

SpliceBio
Contact
clinicaltrials@splice.bio
+34 934 02 04 56

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion